Trials / Unknown
UnknownNCT04975477
CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102)
CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Compensated advanced chronic liver disease (cACLD) was associated with a high rate of variceal bleeding, ascites, and hepatic encephalopathy due to portal hypertension. In these patients, esophagogastroduodenoscopy and hepatic venous pressure gradient were recommended methods to evaluate portal hypertension. However, non-invasive predictors of outcomes to stratify care remains needed. Although the updated EASL guideline has recommended that patients with liver stiffness \>20kPa or platelets \<150\*10\^9/L had the high risk of decompensation, the criteria remains to be validated. This international multicenter study aims to develop a novel CHESS-SAVE score to further predict the risk of liver decompensation in cACLD patients.
Detailed description
Compensated advanced chronic liver disease (cACLD) was associated with a high rate of variceal bleeding, ascites, and hepatic encephalopathy due to portal hypertension. In these patients, esophagogastroduodenoscopy and hepatic venous pressure gradient were recommended methods to evaluate portal hypertension. However, non-invasive predictors of outcomes to stratify care remains needed. Although the updated EASL guideline has recommended that patients with liver stiffness \>20kPa or platelets \<150\*10\^9/L had the high risk of decompensation, the criteria remains to be validated. This international multicenter study initialed and enrolled by Chinese Portal Hypertension Alliance (CHESS) aims to develop a novel CHESS-SAVE score to further predict the risk of liver decompensation in cACLD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Esophagogasrtoduodendoscopy and liver stiffness | Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months. |
| PROCEDURE | hepatic venous pressure gradient | A method was used to evaluate portal pressure. |
Timeline
- Start date
- 2021-07-16
- Primary completion
- 2021-08-16
- Completion
- 2021-08-16
- First posted
- 2021-07-23
- Last updated
- 2021-07-23
Locations
7 sites across 5 countries: China, Egypt, India, Japan, South Korea
Source: ClinicalTrials.gov record NCT04975477. Inclusion in this directory is not an endorsement.